FY2025 EPS Forecast for Puma Biotechnology Raised by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Stock analysts at Zacks Research lifted their FY2025 EPS estimates for shares of Puma Biotechnology in a report issued on Thursday, January 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.28 per share for the year, up from their prior estimate of $0.26. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.06 EPS.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. During the same period in the previous year, the firm posted $0.12 earnings per share.

A number of other analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Trading Down 6.8 %

Shares of PBYI stock opened at $3.31 on Friday. The business has a 50-day moving average of $3.05 and a 200 day moving average of $2.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology has a 1-year low of $2.22 and a 1-year high of $7.73. The stock has a market capitalization of $162.48 million, a PE ratio of 6.90 and a beta of 1.10.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. This represents a 7.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Puma Biotechnology

A number of institutional investors have recently added to or reduced their stakes in PBYI. SG Americas Securities LLC purchased a new stake in shares of Puma Biotechnology in the 3rd quarter worth about $34,000. Franklin Resources Inc. bought a new position in shares of Puma Biotechnology during the third quarter valued at approximately $41,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Puma Biotechnology during the third quarter valued at approximately $44,000. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Royce & Associates LP increased its position in Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.